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Hedgehog (Hh) signaling is recognized 
to contribute to the development and 
progression of many cancers.1 During 
embryonic development, Hh signaling 
is critical for proper cellular differentia-
tion. However, the Hh pathway is largely 
silenced postnatally, making it an attrac-
tive anticancer target. In its resting state, 
the receptor Patched (PTCH) inhibits the 
pathway transducer Smoothened (SMO). 
Binding of the ligands Indian, Desert, or 
Sonic Hh (SHH) to PTCH releases SMO, 
resulting in the activation of downstream 
signaling (which involves GLI transcrip-
tion factors) that mediates increased cel-
lular proliferation and survival.
To date, 7 small molecule inhibitors of 
SMO have entered clinical trials, while com-
pounds targeting additional components 
of the Hh pathway are under preclinical 
development.1 As targeted therapies, SMO 
antagonists have demonstrated safety and 
efficacy in tumors with ligand-independent 
Hh pathway activation due to mutations in 
PTCH or SMO. Following these encour-
aging clinical results, vismodegib has been 
granted FDA approval for the treatment of 
basal cell carcinoma, although it is impor-
tant to note that even responsive tumors 
may develop resistance.2 The clinical effi-
cacy of SMO antagonists in other tumor 
types remains unclear, with some trials sus-
pended due to the absence of clinical benefit. 
This apparent inefficacy may be attributed 
to the fact that the pro-tumorigenic effects 
Hedgehog-targeted therapeutics uncouple  
the vicious cycle of bone metastasis
Michelle A. hurchla and Katherine N. weilbaecher
Department of Medicine; Division of Oncology; washington university school of Medicine; st. Louis, MO usA
Keywords: bone metastasis, hedgehog, osteoclast, SMO antagonist, sonic hedgehog, tumor microenvironment
Correspondence to: Michelle A. Hurchla and Katherine N. Weilbaecher; Email: mhurchla@dom.wustl.edu and kweilbae@dom.wustl.edu
Submitted: 06/04/12; Accepted: 06/08/12
http://dx.doi.org/10.4161/onci.21060
of Hh signaling in many settings is a result 
of enhanced paracrine stimulation of host 
components, rather than of direct effects on 
malignant cells.
For several years, paracrine Hh signal-
ing between tumors and stroma has been 
recognized to support malignant growth.3 
Our recent Cancer Research report4 and 
those of others5–8 suggest that Hh-targeted 
therapeutics may be particularly efficient 
for tumors that arise within the bone 
(i.e., multiple myeloma, osteosarcoma) or 
metastasize to bones (i.e., breast, prostate 
and lung cancer) due to effects on host 
cells within this microenvironment. The 
bone is a preferred site of tumor growth, 
containing abundant growth factors such 
as transforming growth factor β (TGFβ) 
and bone morphogenic proteins (BMPs) 
stored within the mineralized matrix and 
released by bone-resorbing osteoclasts 
(OCs). In turn, tumor-derived factors 
such as osteopontin, PTHrP and interleu-
kin-6 (IL-6) deregulate bone remodeling, 
resulting in excessive activation of OCs 
generating osteolytic lesions and/or bone-
forming osteoblasts (OBs) causing osteo-
blastic lesions. This self-perpetuating 
cycle of tumor growth and bone abnor-
malities is known as the “vicious cycle.”9 
Similar tumor-supporting cycles involv-
ing stromal and immune cells as well as 
components of the extracellular matrix 
have also been described for tumors devel-
oping in non-bone anatomical locations.
Our data suggest that paracrine Hh 
signaling can increase tumor growth 
through direct actions on stromal cells 
including OCs (Fig. 1).4 We first demon-
strated that genetic deletion or pharma-
cological antagonism of SMO inhibited 
the differentiation and bone resorption 
function of OCs, revealing a previously 
undescribed cell-autonomous role for 
Hh signaling in cells of the OC lineage. 
Conversely, mice with constitutive Hh 
pathway signaling due to the heterozy-
gous loss of the inhibitory receptor PTCH 
(Ptch+/−) exhibited increased OC activity. 
Further, we demonstrated that the spe-
cific enhancement of Hh signaling in host 
cells resulted in increased subcutaneous 
growth and bone-metastatic potential in 
Ptch+/− mice, attributed to both the mes-
enchymal and hematopoietic compart-
ments. Together, these data demonstrate 
that regulated Hh signaling is critical for 
normal OC maturation and function and 
that enhanced Hh signaling in host cells 
promotes tumor growth.
Downstream activating mutations or 
alterations that prevent the binding of 
SMO to PTCH render a significant por-
tion of tumors resistant to SMO antago-
nists, limiting their clinical use. As such, 
MDA-MB-231 human breast cancer cells 
are resistant to direct cytotoxic effects by 
SMO antagonists due to undetectable 
SMO expression. This system allowed us 
to precisely examine the effects of SMO 
Paracrine hedgehog (hh) signaling, in which tumor-derived hh ligands activate stromal cells, has been implicated in the 
development and progression of many cancers. recent data suggest that hh-targeted therapeutics exert direct effects 
on host cells, thus interrupting a ”vicious cycle” to bone metastasis that involves osteoblasts, osteoclasts, and tumor cells.
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sub-population.10 Altogether, these obser-
vations suggest that the benefits of Hh 
inhibition may be most apparent in an 
adjuvant setting, in which the prevention 
of recurrence or metastasis follows the 
eradication of the primary tumor with 
conventional or targeted therapeutics. We 
propose that Hh-targeted therapeutics may 
be particularly attractive for the treatment 
and prevention of bone metastasis, as they 
effectively interrupt the “vicious cycle” of 
pro-tumor interactions between OB, OC 
and tumor cells. In ongoing preclinical 
and Phase II clinical studies, we are explor-
ing the effects that SMO antagonists exert 
in preventing the survival and expansion of 
residual bone-marrow disseminated tumor 
cells (DTCs) in patients with high-risk 
localized breast cancer.
cytokine IL-6. Accordingly, knockdown 
of SHH in MDA-MB-231 cells resulted 
in decreased tumor growth in vivo. Taken 
together, these data provide evidence that 
Hh-targeted agents may offer a clinical 
benefit even in the context of Hh resistant 
tumors. In this scenario, SMO inhibitors 
would act on host cells, rendering them 
unresponsive to tumoral Hh ligands and 
changing the microenvironment into one 
that is less supportive of tumor growth.
Our data, along with that of several 
other groups,5–8 underscore the beneficial 
effects resulting from Hh inhibition in 
host cells. The Hh pathway has also been 
implicated in the maintenance of a “can-
cer stem cell” compartment, implying 
that Hh inhibitors may exert substantial 
effect specifically on this rare, long-lived 
inhibitors on the tumor microenviron-
ment. Interestingly, MDA-MB-231 cells 
express high levels of the ligand SHH, yet 
cannot respond to it in an autocrine fash-
ion. We hypothesized that the production 
of SHH by tumor cells would promote a 
paracrine signaling pathway and stimu-
late Hh signaling in host cells. Therefore, 
targeting SMO specifically within stromal 
cells would effectively block the supply of 
pro-tumorigenic growth factors. Indeed, 
the SMO inhibitor LDE225 (which is 
currently being tested in Phase II clini-
cal trials) decreased the growth of resis-
tant MDA-MB-231 cells in vivo. We 
demonstrated that tumor-derived SHH 
induced paracrine signaling in bone mar-
row stromal cells, resulting in increased 
expression of the pro-tumorigenic 
Figure 1. tumor cell production of the hh ligand shh stimulates the vicious cycle of bone metastasis. tumor-derived shh acts in a paracrine manner 
to stimulate hh signaling in host cells within the bone microenvironment. hh signaling in bone marrow stromal cells augments production of factors 
that promote tumor growth including, but not limited to, interleukin-6 (IL-6). shh also induces osteoblastic commitment. Osteoblasts express rANK 
ligand (rANKL), which binds to rANK on myeloid progenitors leading to the formation of multinucleated, bone-resorbing osteoclasts. hh signaling 
also exerts cell-autonomous effects on osteoclast differentiation and function. Finally, osteoclastic bone resorption releases growth factors such as 
transforming growth factor β (tGFβ) and bone morphogenic proteins (BMPs) from the mineralized matrix, further enhancing tumor growth and sur-
vival. this creates a ‘vicious cycle’ in which tumor-derived factors such as shh, along with other known osteolytic factors (gray box), deregulate bone 
remodeling (solid black lines), while stimulating the production of pro-tumorigenic factors (dashed gray lines). this self-perpetuating cycle results in 
increased tumor burden and bone destruction.
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